What's in Par Pharmaceutical, Inc.'s pipeline?

Par Pharmaceutical, Inc. has 13 drugs in our index: 9 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 4 in Phase 1.

Which companies overlap with Par Pharmaceutical, Inc.'s portfolio?

Top competitors by shared drug class: Sumitomo Pharma (Suzhou) Co., Ltd., Supernus Pharmaceuticals, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/par-pharmaceutical-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Par Pharmaceutical, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Par Pharmaceutical, Inc. pipeline: 9 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

9 marketed 0 filed 0 Phase 3 0 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Monodox	Monodox	marketed			Other
Buspar	Buspar	marketed			Other
Parnate	Parnate	marketed		7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Cytochrome P450 2B6, Lysine-specific histone demethylase 1B	Neuroscience
ARAVA	ARAVA	marketed
Inderal-LA	Inderal-LA	marketed
Flagyl	Flagyl	marketed			Other
Buspirone HCl	Buspirone HCl	marketed	5-HT1A receptor agonist	5-HT1A receptor	Psychiatry/Neurology
Klonopin	Klonopin	marketed		GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel	Neuroscience
Oxandrin	Oxandrin	marketed		Androgen receptor	Other

Therapeutic area mix

Other · 6
Neuroscience · 2
Psychiatry/Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sumitomo Pharma (Suzhou) Co., Ltd. · 1 shared drug class
Supernus Pharmaceuticals, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Par Pharmaceutical, Inc.:

Cite this brief

Drug Landscape (2026). Par Pharmaceutical, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/par-pharmaceutical-inc. Accessed 2026-06-10.